Mucosal dendritic cell surface proteins

Mucosal dendritic cell surface proteins refer to a heterogeneous group of molecules expressed on the surface of specialized dendritic cells (DCs) located in mucosal tissues, such as the gastrointestinal tract and respiratory system. These proteins, including CD103 (Integrin alpha E), DC-SIGN (CD209), and various Toll-like receptors (TLRs), are critical for maintaining immune homeostasis by balancing tolerance to harmless commensal antigens with active immunity against pathogens (Mann et al., 2013; Coombes et al., 2007). In inflammatory conditions like Crohn's disease and ulcerative colitis, the expression and function of these surface proteins are often dysregulated, contributing to chronic inflammation and aberrant T-cell activation (Hart et al., 2005). Therapeutic interventions often target specific members of this group; for example, Etrolizumab targets the alphaEbeta7 integrin (which includes the mucosal DC marker CD103) to modulate immune cell localization (Vermeire et al., 2014). Other drugs like Vedolizumab target the alpha4beta7 integrin, which interacts with mucosal addressins to facilitate cell homing to these tissues. Because this term describes a broad category of proteins rather than a single molecular entity, it is generally classified as an incorrect target designation for specific drug development purposes. Understanding the specific profile of these surface proteins is essential for developing targeted mucosal vaccines and therapies for autoimmune diseases.

Other names

Mucosal DC surface markersGut dendritic cell antigensMucosal dendritic cell receptors

Inhibition of leukocyte trafficking to mucosal sites and modulation of T-cell differentiation by blocking interactions between mucosal dendritic cell surface receptors and their ligands.